After 15 years, more than 8 out of 10 patients in the maximum dose exposure group did not need a walking aid.3
86% of PRISMS-15 patients consistently taking Rebif® had Expanded Disability Status Scale (EDSS) <6.0 (defined as ambulatory, without aid of a cane, crutch or brace) after 15 years.
The PRISMS-15 study was a single-visit follow-up and analyses were exploratory; results should be interpreted with caution.
After 15 years, more than 8 out of 10 patients in the maximum dose exposure group did not need a walking aid.386% of PRISMS-15 patients consistently taking Rebif® had Expanded Disability Status Scale (EDSS) <6.0 (defined as ambulatory, without aid of a cane, crutch or brace) after 15 years. The PRISMS-15 study was a single-visit follow-up and analyses were exploratory; results should be interpreted with caution.
8 out of 10 patients receiving Rebif® for up to 8 years did not progress to secondary progressive MS (SPMS).9
80% of PRISMS-7/8 patients receiving Rebif® for up to 8 years did not progress to SPMS.9
The PRISMS-7/8 study was a single visit follow-up and analyses are exploratory; results should be interpreted with caution.
8 out of 10 patients receiving Rebif® for up to 8 years did not progress to secondary progressive MS (SPMS).980% of PRISMS-7/8 patients receiving Rebif® for up to 8 years did not progress to SPMS.9 The PRISMS-7/8 study was a single visit follow-up and analyses are exploratory; results should be interpreted with caution.*Exploratory efficacy endpoint